𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Production of Glycosylated Heparin-Binding EGF-like Growth Factor in HeLa Cells Using Vaccinia Virus

✍ Scribed by Karen M. Davis; David R. Brigstock; Philip R. Johnson; Melissa A. Crissman-Combs; Diane W. McCarthy; Marc T. Downing; Gail E. Besner

Book ID
115645044
Publisher
Elsevier Science
Year
1996
Tongue
English
Weight
468 KB
Volume
8
Category
Article
ISSN
1046-5928

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

High glucose and hyperosmolarity increas
High glucose and hyperosmolarity increase heparin-binding epidermal growth factor-like growth factor (HB-EGF) production in cultured human aortic endothelial cells
✍ Hideki Asakawa; Jun-Ichiro Miyagawa; Shigeki Higashiyama; Katsutoshi Goishi; Tos πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 900 KB

## Abstract Heparin‐binding epidermal growth factor‐like growth factor (HB‐EGF) has been shown to be a potent smooth muscle cell (SMC) mitogen and chemoattractant, and might be a candidate factor for the progression of atherosclerosis. We have investigated the effects of high glucose and hyperosmol

Induction of heparin-binding EGF-like gr
Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells
✍ Faye M. Johnson; Babita Saigal; Nicholas J. Donato πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 459 KB

Imatinib mesylate is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases. Inhibition of BCR-ABL and c-kit accounts for its clinical activity in leukemia and sarcoma, respectively. In this report, we describe other cellular targets for imatinib.